Apabetalone is under clinical development by Resverlogix and currently in the Phase I and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Apabetalone’s likelihood of approval (LoA) and phase transition for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) took place on 25 Aug 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Apabetalone Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Apabetalone overview

Apabetalone (RVX-208) is under development for the treatment of coronary artery disease, rheumatoid arthritis, peripheral artery disease, chronic kidney disease, retinal degeneration, pulmonary arterial hypertension,  vascular cognitive dementia, complement mediated disease, and coronavirus disease 2019 (COVID-19). It is administered orally.  It targets the BD2 domain of the BRD4 (bromodomain-containing protein 4) belonging to the BET (bromodomain and extra-terminal domain) family. The drug candidate is developed based on the company’s proprietary NexVas platform. It was also under development for the treatment of dyslipidemia and Alzheimer’s disease, rheumatoid arthritis, pre-diabetes mellitus and paroxysmal nocturnal hemoglobinuria.

It was under development for the treatment for fabry disease, vascular dementias, facioscapulohumeral muscular dystrophy (FSHD), human immunodeficiency virus infections, malignant peripheral nerve sheath tumors (MPNST) and cognitive disorders.

Resverlogix overview

Resverlogix is a biotechnology company which develops small molecule therapeutics for cardiovascular disease, diabetes mellitus, and chronic kidney disease. The company’s lead product candidate include Apabetalone (RVX-208) is a first-in-class small molecule that inhibits BET bromodomain proteins for the treatment of high-risk cardiovascular disease patients with type 2 diabetes mellitus and low high-density lipoprotein (HDL), and Alzheimer’s disease. Resverlogix utilizes an epigenetics drug development platform, BET technology that targets BET proteins and identify small molecule candidates that specifically bind to BET bromodomains and regulate gene expression, among others. It also discovers and develops therapeutics for neurodegenerative diseases, peripheral artery disease and rare orphan diseases. The company operates through its representative office located in San Francisco, California, the US. Resverlogix is headquartered in Calgary, Alberta, Canada.

Quick View Apabetalone LOA Data

Report Segments
  • Innovator
Drug Name
  • Apabetalone
Administration Pathway
  • Oral
Therapeutic Areas
  • Cardiovascular
  • Central Nervous System
  • Genetic Disorders
  • Genito Urinary System And Sex Hormones
  • Hematological Disorders
  • Immunology
  • Infectious Disease
  • Metabolic Disorders
  • Musculoskeletal Disorders
  • Oncology
  • Ophthalmology
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.